UNSPSC 51201810: Galsulfase

This classification denotes an enzyme replacement preparation with the molecular formula C2529H3843N689O716S16, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 59UA429E5G, more generally known as galsulfase. European Medicines Agency schedules galsulfase in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21229. The term GALSULFASE is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 19, no. 3, 2005, list 54.

Most nations schedule galsulfase under HS 35079090 and SITC 51691. As of Q4 2014, GALSULFASE remains the US FDA Preferred Term for this commodity. Galsulfase bears US NLM identifiers UMLS ID C1615657 and NCI Concept Code C74207. SMILES: NONE.

UNSPSC 51201810 Galsulfase, a Commodity code, nominally describes a specific enzyme replacement therapy, but recent state and local procurement activity under this code does not align with the taxonomy name. The Mississippi State Department of Health posted a sole source procurement notice in July 2026 for Yellow Fever Vaccine from Sanofi Pasteur, Inc., a biological immunization product unrelated to galsulfase. The mismatch suggests either a data-entry error in the state procurement system or a coding artifact; the opportunity does not represent actual galsulfase procurement at the state or local level.

The source contains no additional recent opportunities under UNSPSC 51201810 and provides no evidence of broader state or local buying activity for galsulfase itself. Without corroborating opportunities, issuing-body patterns, or geographic concentration data, no actionable market characterization is possible under this code. Business development professionals should treat this code as inactive for state and local procurement purposes and verify coding assignments in any future solicitation appearing under 51201810 before committing pursuit resources.